Women who used ibuprofen or acetaminophen for 6 years or more were at higher risk of hearing loss than those who used these medications for a year or less.
BRIGHAM AND WOMEN'S HOSPITAL - Boston, MA -- As many as two-thirds of women in the United States over the age of 60 have some degree of hearing loss. Using data from the Nurses' Health Study, a team led by researchers from Brigham and Women's Hospital has found evidence that the duration of use of over-the-counter medications for pain relief, including ibuprofen or acetaminophen, is associated with higher risk of hearing loss. The new study, published on Dec. 14 in the American Journal of Epidemiology adds to a growing body of evidence linking the use of non-steroidal anti-inflammatory drugs (NSAIDS) or acetaminophen with loss of hearing, although the exact mechanism at play remains unknown.
"Hearing loss is extremely common in the United States and can have a profound impact on quality of life," said senior author Gary Curhan, MD, SCD, a physician in the Channing Division of Network Medicine at Brigham and Women's Hospital. "Finding modifiable risk factors could help us identify ways to lower risk before hearing loss begins and slow progression in those with hearing loss."
The research team examined data from more than 54,000 women between the ages of 48 and 73 enrolled in the Nurses' Health Study. They analyzed information on usage of aspirin, ibuprofen and acetaminophen, as well as self-reported hearing loss.
Longer duration of ibuprofen or acetaminophen use was associated with higher risk of hearing loss. The team did not find a significant association between hearing loss and duration of usual-dose aspirin use. (Hearing loss is an established side effect of high dosages of aspirin, but such dosages have become uncommon over the last two decades.)
"Although the magnitude of higher risk of hearing loss with analgesic use was modest, given how commonly these medications are used, even a small increase in risk could have important health implications. Assuming causality, this would mean that approximately 5.5 percent of hearing loss occurring in these women could be due to ibuprofen or acetaminophen use," said Curhan. The study's authors note that the NHS data are limited to mostly older, white women and that further investigation in larger groups and among other populations will be important to understand the connection between hearing loss and pain reliever usage. The team has previously published findings that indicate that higher frequency use of NSAIDs and acetaminophen are associated with higher risk of hearing loss in men and younger women.
###
This work was supported by grants U01 DC010811 and UM1 CA176726 from the National Institutes of Health.
Brigham and Women's Hospital (BWH) is a 793-bed nonprofit teaching affiliate of Harvard Medical School and a founding member of Partners HealthCare. BWH has more than 4.2 million annual patient visits and nearly 46,000 inpatient stays, is the largest birthing center in Massachusetts and employs nearly 16,000 people. The Brigham's medical preeminence dates back to 1832, and today that rich history in clinical care is coupled with its national leadership in patient care, quality improvement and patient safety initiatives, and its dedication to research, innovation, community engagement and educating and training the next generation of health care professionals. Through investigation and discovery conducted at its Brigham Research Institute (BRI), BWH is an international leader in basic, clinical and translational research on human diseases, more than 3,000 researchers, including physician-investigators and renowned biomedical scientists and faculty supported by nearly $666 million in funding. For the last 25 years, BWH ranked second in research funding from the National Institutes of Health (NIH) among independent hospitals. BWH is also home to major landmark epidemiologic population studies, including the Nurses' and Physicians' Health Studies and the Women's Health Initiative as well as the TIMI Study Group, one of the premier cardiovascular clinical trials groups. For more information, resources and to follow us on social media, please visit BWH's online newsroom.
Source: https://www.eurekalert.org
